Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 20:2021:8858962.
doi: 10.1155/2021/8858962. eCollection 2021.

Evaluation of Beneficial and Adverse Effects of a Diet Supplemented with Schisandrae Fructus Seed Ethanol Extract on Lipid and Glucose Metabolism in Normal and Hypercholesterolemic/Hyperglycemic Mice

Affiliations

Evaluation of Beneficial and Adverse Effects of a Diet Supplemented with Schisandrae Fructus Seed Ethanol Extract on Lipid and Glucose Metabolism in Normal and Hypercholesterolemic/Hyperglycemic Mice

Xiao-Yan Wang et al. Evid Based Complement Alternat Med. .

Abstract

Schisandrae Fructus (SF), the fruit of Schisandra chinensis (Turcz.) Baillon, has been used for the treatment of liver injury and metabolism-related disorders in China. The objective of this study was to investigate the effects of supplementation with ethanol extract of SF seed (EtSF-S) on serum/hepatic lipid and glucose levels as well as fecal total cholesterol (TC) contents in mice fed a normal diet (ND) or high-fat/fructose diet (HFFD) containing 15% lard oil and 15% fructose. Female ICR mice (18-20 g in body weight) were fed with ND or HFFD for 3 months, and then EtSF-S was added to both chow diets at increasing concentrations of 1, 5, and 10% (w/w). Thirty days later, serum and hepatic lipids, including TC, triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and glucose, were measured. Dietary supplementation with EtSF-S reduced hepatic TC (36 and 18%) and TG levels (38 and 28%) and increased serum HDL/LDL ratio (16 and 26%) in both ND- and HFFD-fed mice, respectively. Moreover, supplementation with EtSF-S elevated serum HDL (31%) in HFFD-fed mice and reduced serum LDL (27%) in ND-fed mice. EtSF-S treatment reduced fat mass (40%) in ND-fed mice and increased fecal TC contents (33%) in HFFD-fed mice. EtSF-S supplementation decreased hepatic glucose contents (29%) in both ND- and HFFD-fed mice. However, diet supplemented with EtSF-S elevated serum TG levels (up to 123%) and hepatic size (28%), but more importantly, suppressed the body weight gain (approximately 130%) in mice fed with HFFD. These findings suggested that dietary supplementation with EtSF-S as natural herbal function food may be a useful strategy for the treatment of patients with fatty liver disease or overweight without a high intake of sugar and fat.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
The experimental protocol of the present study.
Figure 2
Figure 2
HPLC chromatogram of reference substance (a) and EtSF-S (b). (1) Schisandrol A; (2) schisandrin A; (3) schisandrin B (Sch B).
Figure 3
Figure 3
Effect of dietary supplementation with EtSF-S or FF on serum, hepatic, and fecal lipids in ND- and HFFD-fed mice. Mice were fed with normal diet (ND) or high fructose/fat diet (HFFD) for 3 months. Then, animals were fed with ND or HFFD without and with supplementation with the ethanol extract of Schisandrae Fructus (SF) seed (EtSF-S) or fenofibrate (FF). After 30 days of experiment, serum and hepatic total cholesterol (TC) and triacylglycerol (TG) levels including fecal TC contents were measured. The concentrations of EtSF-S in chow diet were estimated on the basis of crude herbal material (SF seed). Values given are the mean ± SD, with N = 10. p < 0.05, ∗∗p < 0.01 vs. ND alone; p < 0.05, ††p < 0.01 vs. HFFD alone.
Figure 4
Figure 4
The summary of the present study.

References

    1. Lowndes J., Sinnett S., Yu Z., Rippe J. The effects of fructose-containing sugars on weight, body composition and cardiometabolic risk factors when consumed at up to the 90th percentile population consumption level for fructose. Nutrients. 2014;6(8):3153–3168. doi: 10.3390/nu6083153. - DOI - PMC - PubMed
    1. Schwab U., Lauritzen L., Tholstrup T., et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food & Nutrition Research. 2014;58(1) doi: 10.3402/fnr.v58.25145.25145 - DOI - PMC - PubMed
    1. Ben M. D., Polimeni L., Baratta F., Pastori D., Loffredo L., Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(26):8341–8350. doi: 10.3748/wjg.v20.i26.8341. - DOI - PMC - PubMed
    1. Liu H., Lu H. Y. Nonalcoholic fatty liver disease and cardiovascular disease. World Journal of Gastroenterology. 2014;20(26):8407–8415. doi: 10.3748/wjg.v20.i26.8407. - DOI - PMC - PubMed
    1. Liu Z. L., Xie L. Z., Zhu J., Li G. Q., Grant S. J., Liu J. P. Herbal medicines for fatty liver diseases. Cochrane. Database Systematic Reviews. 2013;8CD009059 - PubMed

LinkOut - more resources